Clinical Haematology research
Our Clinical Haematology service is affiliated with the laboratory and clinical research conducted by the Australian Centre for Blood Diseases (ACBD).
ACBD is a leading national and international blood diseases centre with recognised research, treatment, and educational programs for blood diseases. ACBD is affiliated with The Alfred, Monash University, Eastern Health and Southern Health.
Research is divided into two main groups:
- Blood cancers and stem cells
- Haemostasis and thrombosis
Prof Harshal Nandurkar is the Director of Clinical Haematology and head of the Australian Centre for Blood Diseases.
Prof Andrew Spencer is the head of our Malignant Haematology & Stem Cell Transplantation Service.
Prof David Curtis is head of the Division of Blood Cancer Research at the Australian Centre for Blood Diseases.
As the Director of Research, Stephen Jane is responsible to the Chief Executive for the strategic direction and governance of research at Alfred Health.
Acute Leukaemia Research Group
Our group focuses on several haematopoietic transcription factors recurrently mutated in acute lymphoblastic and myeloid leukemias (ALL and AML) and their role in tumour suppressor gene function.Find out more
Acute Myeloid Leukaemia Research Group
The Wei and Guthridge research groups focus on the mechanisms by which cancer cells co-opt and coerce intracellular signalling pathways to promote deregulated cell survival, proliferation and growth.Find out more
Leukaemia Signalling Pathways Group
The normal human immune system functions not only to remove infected cells but also to remove damaged or pre-cancerous cells.Find out more
Mammalian Functional Genetics Unit
Our group uses transgenic mouse models and ES / iPS (embryonic stem / induced pluripotent stem) cell-based technologies to study cell fate and cellular transformation at the molecular level.Find out more
Myeloma Research Group
Our group explores novel therapeutic approaches for multiple myeloma (MM) in preclinical and clinical studies.Find out more
Red Cell Research Group
We have developed a novel drug for blocking the activity of an enzyme important for the control of haemoglobin production and growth of blood cancers such as polycythemia and myelofibrosis.Find out more
Stem Cell Biology Group
Our research focuses on the regulation of stem cells in haematopoietic and leukaemic cells through genetic and epigenetic studies.Find out more
Molecular Neurotrauma and Haemostasis Unit
The blood-brain barrier (BBB) becomes compromised in traumatic brain injury (TBI) and ischemic stroke patients, particularly after treatment with the thrombolytic agent tissue-type plasminogen activator (t-PA).Find out more
We are interested in how antibody targeted imaging agents and drug delivery vehicles can improve clinical diagnosis and therapy.Find out more
Platelets and Thrombosis Laboratory
Arterial thrombosis underlies heart attacks and strokes and is the most common cause of death in Australia.Find out more
Systems Haematology Unit
Our group investigates platelet receptor levels in health and disease and how changes result in altered platelet function.Find out more
Vascular Biology Group
Our research aims to identify pathways linking inflammation and thrombosis and to develop novel therapeutics targeted to specific vascular beds.Find out more
The traumatic side of fibrinolysis
(2015), Blood, 125(16), 8/1/2457
The platelet Fc receptor, Fc_RIIa
Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE
(2015), Immunol Rev, 268(1), 241-52
The fibrinolytic system-more than fibrinolysis?
Draxler DF, Medcalf RL
(2015), Transfus Med Rev, 29(2), 102-9